Order Article Reprints

Alzarea SI, Qasim S, Afzal M, Alsaidan OA, Alhassan HH, Alharbi M, Alqinyah M, Alenazi FS. Anandamide Reuptake Inhibitor (VDM11) as a Possible Candidate for COVID-19 Associated Depression; a Combination of Network Pharmacology, Molecular Docking and In Vivo Experimental Analysis. Processes. 2023; 11(1):143. https://doi.org/10.3390/pr11010143

Alzarea, Sami I., Sumera Qasim, Muhammad Afzal, Omar Awad Alsaidan, Hassan H. Alhassan, Metab Alharbi, Mohammed Alqinyah, and Fahaad S. Alenazi. 2023. "Anandamide Reuptake Inhibitor (VDM11) as a Possible Candidate for COVID-19 Associated Depression; a Combination of Network Pharmacology, Molecular Docking and In Vivo Experimental Analysis" Processes 11, no. 1: 143. https://doi.org/10.3390/pr11010143

Alzarea, S. I., Qasim, S., Afzal, M., Alsaidan, O. A., Alhassan, H. H., Alharbi, M., Alqinyah, M., & Alenazi, F. S. (2023). Anandamide Reuptake Inhibitor (VDM11) as a Possible Candidate for COVID-19 Associated Depression; a Combination of Network Pharmacology, Molecular Docking and In Vivo Experimental Analysis. Processes, 11(1), 143. https://doi.org/10.3390/pr11010143